Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EBIT (2024 - 2025)

Kura Oncology (KURA) has disclosed EBIT for 2 consecutive years, with -$80.6 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 379.77% to -$80.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$276.9 million through Dec 2025, down 62.53% year-over-year, with the annual reading at -$58.5 million for FY2025, 61.95% down from the prior year.
  • EBIT for Q4 2025 was -$80.6 million at Kura Oncology, down from -$73.7 million in the prior quarter.
  • The five-year high for EBIT was -$16.8 million in Q4 2024, with the low at -$80.6 million in Q4 2025.